• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
  

PubMed=22751098; DOI=10.1038/ng.2330; PMCID=PMC3408577
Zhang Z.-F., Lee J.C., Lin L.-P., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X.-Q., Levine A.D., Rho J.K., Choi Y.J., Choi C.-M., Kim S.-W., Jang S.J., Park Y.S., Kim W.S., Lee D.H., Lee J.-S., Miller V.A., Arcila M.E., Ladanyi M., Moonsamy P., Sawyers C.L., Boggon T.J., Ma P.C., Costa C., Taron M., Rosell R., Halmos B., Bivona T.G.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Nat. Genet. 44:852-860(2012)

PubMed=32928921; DOI=10.1158/0008-5472.CAN-20-1634; PMCID=PMC11106563
Sun Y.-T., Meyers B.A., Czako B., Leonard P., Mseeh F., Harris A.L., Wu Q., Johnson S., Parker C.A., Cross J.B., Di Francesco M.E., Bivona B.J., Bristow C.A., Burke J.P., Carrillo C.C., Carroll C.L., Chang Q., Feng N.-P., Gao G., Gera S., Giuliani V., Huang J.K., Jiang Y.-Y., Kang Z.-J., Kovacs J.J., Liu C.-Y., Lopez A.M., Ma X.-Y., Mandal P.K., McAfoos T.J., Miller M.A., Mullinax R.A., Peoples M., Ramamoorthy V., Seth S., Spencer N.D., Suzuki E., Williams C.C., Yu S.S., Zuniga A.M., Draetta G.F., Marszalek J.R., Heffernan T.P., Kohl N.E., Jones P.
Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib.
Cancer Res. 80:4840-4853(2020)